前列腺癌对氟他胺撤药的反应。 - Suppr

Suppr

超能文献

Response of carcinoma of the prostate to withdrawal of flutamide.

作者信息

Collinson M P, Daniel F, Tyrrell C J, Teasdale C

机构信息

Research Unit, Plymouth General Hospital.

出版信息

Br J Urol. 1993 Nov;72(5 Pt 1):662-3. doi: 10.1111/j.1464-410x.1993.tb16234.x.

DOI:10.1111/j.1464-410x.1993.tb16234.x

PMID:10071562

Abstract

摘要

相似文献

Response of carcinoma of the prostate to withdrawal of flutamide.前列腺癌对氟他胺撤药的反应。

Br J Urol. 1993 Nov;72(5 Pt 1):662-3. doi: 10.1111/j.1464-410x.1993.tb16234.x.

The antiandrogen withdrawal syndrome in relapsed prostate cancer.

Eur Urol. 1997;31 Suppl 2:3-7; discussion 24-7. doi: 10.1159/000474540.

Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.尽管疾病进展，但氟他胺撤药综合征中前列腺特异性抗原反应持续存在。

South Med J. 1998 Jun;91(6):573-5. doi: 10.1097/00007611-199806000-00013.

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.抗雄激素撤药综合征。一大群未经选择的晚期前列腺癌患者的经验。

Cancer. 1995 Oct 15;76(8):1428-34. doi: 10.1002/1097-0142(19951015)76:8<1428::aid-cncr2820760820>3.0.co;2-t.

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.静脉注射帕米膦酸盐对接受联合雄激素阻断治疗的前列腺癌男性的抗骨质疏松疗效：一项双盲、随机、安慰剂对照交叉研究。

Cancer. 2001 Sep 15;92(6):1444-50. doi: 10.1002/1097-0142(20010915)92:6<1444::aid-cncr1468>3.0.co;2-m.

Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.加拿大多中心III期随机试验的最终报告：针对临床局限性前列腺癌，在常规剂量放疗前进行3个月与8个月新辅助雄激素剥夺治疗的对比研究

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):327-33. doi: 10.1016/j.ijrobp.2008.04.075. Epub 2008 Aug 15.

Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.关于：血清前列腺特异性抗原在停用氟他胺后下降的雄激素非依赖性前列腺癌患者的特征分析

J Urol. 1997 Aug;158(2):552. doi: 10.1016/s0022-5347(01)64545-2.

Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.非那雄胺联合氟他胺或戈舍瑞林作为前列腺M1期癌患者的联合激素治疗。国际前列腺健康委员会（IPHC）试验研究组。

Prostate. 1999 Jul 1;40(2):105-14. doi: 10.1002/(sici)1097-0045(19990701)40:2<105::aid-pros6>3.0.co;2-9.

Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.新辅助治疗替加氟联合氟他胺治疗临床 T3、T4 期前列腺癌：西南肿瘤协作组 9109 研究的 10 年随访结果

Urology. 2012 Mar;79(3):633-7. doi: 10.1016/j.urology.2011.11.019.

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.联合雄激素阻断对前列腺癌男性患者骨转换和骨密度的影响：纵向评估及对间歇性周期性依替膦酸治疗的反应

Cancer. 1998 Oct 15;83(8):1561-6.

引用本文的文献

Blockade of testicular and adrenal androgens in prostate cancer treatment.阻断前列腺癌治疗中的睾丸和肾上腺雄激素。

Nat Rev Urol. 2011 Feb;8(2):73-85. doi: 10.1038/nrurol.2010.231. Epub 2011 Jan 18.

A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.雄激素拮抗剂撤药反应显著：病例报告及文献复习。

J Hematol Oncol. 2008 Nov 5;1:21. doi: 10.1186/1756-8722-1-21.

Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.与前列腺癌治疗相关的抗雄激素撤药综合征：发生率及临床意义。

Drug Saf. 2000 Nov;23(5):381-90. doi: 10.2165/00002018-200023050-00003.

Bicalutamide in advanced prostate cancer. A review.比卡鲁胺治疗晚期前列腺癌。综述。

Drugs Aging. 1998 May;12(5):401-22. doi: 10.2165/00002512-199812050-00006.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验